STOCK TITAN

Gilead (GILD) insider Daniel O'Day reports multiple 10,000-share sales

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 filing by an insider of Gilead Sciences (GILD) reporting proposed and recent sales of common stock. The notice shows a proposed sale of 10,000 shares to be executed through Morgan Stanley Smith Barney on 09/29/2025 with an aggregate market value of $1,116,564.00. The shares were originally acquired as restricted stock on 03/01/2020. The filing also discloses three completed sales by the same person, DANIEL O'DAY, of 10,000 shares each on 06/30/2025, 07/28/2025, and 08/28/2025 for gross proceeds of $1,104,483.00, $1,139,369.00, and $1,136,300.00, respectively. The filing lists 1,240,806,916 shares outstanding for the class and identifies NASDAQ as the exchange.

Positive

  • Transparent disclosure of recent and proposed insider sales including dates, amounts, and gross proceeds
  • Origin of shares documented as restricted stock acquired from the issuer on 03/01/2020
  • Broker identified for the proposed sale (Morgan Stanley Smith Barney) and exchange listed (NASDAQ)

Negative

  • None.

Insights

TL;DR: Insider sales totaling 40,000 shares were disclosed, including a planned 10,000-share sale; this appears to be routine liquidity activity.

The filing documents routine Section 16/Rule 144 activity by an insider identified as Daniel O'Day. Three sales in the past three months total 30,000 shares with combined gross proceeds of $3,380,152.00. A proposed sale of 10,000 shares is scheduled for 09/29/2025 with an indicated market value of $1,116,564.00. The shares were originally received as restricted stock on 03/01/2020, which suggests vesting or availability for sale rather than an open-market accumulation or divestiture tied to new information. On the face of the form there is no allegation of undisclosed material information. Impact on equity float is immaterial relative to the reported 1,240,806,916 shares outstanding.

TL;DR: Disclosure aligns with Rule 144 requirements; sales are documented and signed statements assert no undisclosed material information.

The filer certifies lack of material nonpublic information and provides transaction provenance showing acquisition as restricted stock from the issuer on 03/01/2020. The record of multiple monthly sales and a scheduled sale indicates reliance on applicable exemptions and reporting obligations. From a governance perspective, the form contains the expected attestations and broker identification (Morgan Stanley Smith Barney). There is no indication in this filing of unusual trading patterns or regulatory exceptions.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What insider sales does the GILD Form 144 report show?

The filing reports three completed sales of 10,000 shares each on 06/30/2025, 07/28/2025, and 08/28/2025 and a proposed sale of 10,000 shares scheduled for 09/29/2025.

Who is the seller named in the filing for GILD?

The filing identifies the seller as DANIEL O'DAY with an address listed in Foster City, CA.

What were the gross proceeds from the recent sales disclosed?

Gross proceeds reported are $1,104,483.00 (06/30/2025), $1,139,369.00 (07/28/2025), and $1,136,300.00 (08/28/2025).

How many shares does the Form 144 propose to sell on 09/29/2025 and what is the market value?

The proposed sale is 10,000 shares with an aggregate market value of $1,116,564.00.

When and how were the shares being sold originally acquired?

The shares were acquired as restricted stock from the issuer on 03/01/2020.
Gilead Sciences Inc

NASDAQ:GILD

GILD Rankings

GILD Latest News

GILD Latest SEC Filings

GILD Stock Data

155.92B
1.24B
0.1%
90.75%
1.42%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States
FOSTER CITY